Document Detail

Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
MedLine Citation:
PMID:  8641009     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Thrombolysis to normal flow in patients with acute myocardial infarction preserves left ventricular function and decreases mortality. Failure of early reperfusion, reocclusion, or residual thrombus may be due to concurrent activation of the platelet-coagulation system. Thus, we hypothesized that the best concomitant antithrombotic therapy (recombinant [r]-hirudin, heparin, or aspirin) will maximally accelerate thrombolysis by r-tissue-type plasminogen activator (rTPA) and reduce residual thrombus. METHODS AND RESULTS: Occlusive thrombi were formed in the carotid arteries of 29 pigs (by balloon dilatation followed by endarterectomy at the site of injury-induced vasospasm) and matured for 30 minutes before rTPA was started, with or without antithrombotic therapy. Thrombolysis was assessed with the use of angiography and measurement of residual thrombus. Pigs were allocated to one of five treatments: placebo, rTPA, rTPA plus r-hirudin, rTPA plus heparin, or rTPA plus intravenous aspirin. No placebo-treated pig reperfused. Two of six animals treated with rTPA alone reperfused compared with seven of seven animals treated with rTPA plus r-hirudin (reperfusion time, 33 +/- 10 minutes), six of seven animals treated with rTPA plus heparin (reperfusion time, 110 +/- 31 minutes), and two of six animals with rTPA plus aspirin. The activated partial thromboplastin time was prolonged in only the rTPA plus r-hirudin group (25 +/- 0.1 times baseline) and the rTPA plus heparin group (5.3 +/- 0.2 times baseline). Residual 111In-platelet and 125I-fibrin(ogen) depositions were lower in the heparin-treated group and lowest in the r-hirudin-treated group (heparin versus hirudin, respectively; incidence of residual macroscopic thrombus was six of six animals versus two of seven [P = .01]; 125I-fibrin(ogen), 170 +/- 76 versus 48 +/- 6 x 10(6) molecules/cm2 [P = .02]; 111In-platelets, 47 +/- 15 versus 13 +/- 2 x 10(6)/cm2, P = .10). No pigs developed spontaneous bleeding. CONCLUSIONS: Thrombin inhibition with heparin or r-hirudin significantly accelerated thrombolysis of occlusive platelet-rich thrombosis, but only the best antithrombotic therapy (r-hirudin) eliminated or nearly eliminated residual thrombus.
J S Mruk; P Zoldhelyi; M W Webster; M Heras; D E Grill; D R Holmes; V Fuster; J H Chesebro
Related Documents :
7982419 - Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfar...
19663529 - Cost effectiveness of fondaparinux in non-st-elevation acute coronary syndrome.
11567679 - Oral glycoprotein iib/iia antagonists for unstable angina--is there still a chance for ...
18195669 - Antiplatelet agents and randomized trials.
16721199 - Which strategy should be used for acute st-elevation myocardial infarction in patients ...
2868029 - Persantine-aspirin reinfarction study. part ii. secondary coronary prevention with pers...
12297889 - Molecular embryogenesis of the heart.
22177469 - Reverse left ventricular remodeling is more likely in non ischemic cardiomyopathy patie...
11666099 - Appropriateness of the use of coronary angiography in a population of patients with isc...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Circulation     Volume:  93     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1996 Feb 
Date Detail:
Created Date:  1996-07-15     Completed Date:  1996-07-15     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  792-9     Citation Subset:  AIM; IM    
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aspirin / administration & dosage,  therapeutic use*
Blood Platelets / drug effects,  pathology
Carotid Arteries / drug effects,  metabolism,  pathology
Drug Therapy, Combination
Fibrin / metabolism
Fibrinolytic Agents / administration & dosage,  therapeutic use*
Heparin / administration & dosage,  therapeutic use*
Hirudin Therapy*
Hirudins / administration & dosage
Recombinant Proteins / administration & dosage,  therapeutic use
Thrombosis / drug therapy*,  pathology
Time Factors
Tissue Plasminogen Activator / administration & dosage,  therapeutic use
Grant Support
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Hirudins; 0/Recombinant Proteins; 50-78-2/Aspirin; 9001-31-4/Fibrin; 9005-49-6/Heparin; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioni...
Next Document:  Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combin...